孟鲁司特联合信必可治疗儿童哮喘的疗效观察

目的观察孟鲁司特联合信必可治疗儿童哮喘的临床疗效。方法将62例轻中度哮喘患儿随机分为两组,实验组（32例）：给予信必可都保（布地奈德/福莫特罗复方制剂）80/4.5μg/吸,每日两次吸入,加孟鲁司特治疗（5 mg/次,每天一次,睡前口服）;对照组（30例）：信必可都保80/4.5μg/吸,每日两次吸入治疗,未加孟鲁司特。共12周,观察两组患儿临床控制情况及肺功能（PEF、FEV1、FEF75、FEF50、FEF25）改变。结果（1）临床控制率：实验组临床控制率93.7%;对照组临床控制率86.7%,两组比较差异无统计学意义（P〉0.05）;（2）肺功能改善情况：实验组FEV1、PEF、FEF75、FEF50、FEF25较治疗前明显改善,差异有统计学意义（P〈0.01）;与对照组比较PEV1、PEF改善率差异无统计学意义（P〉0.05）,小气道功能（FEF75、FEF50、FEF25）改善率差异有统计学意义（P〈0.05）。结论孟鲁司特联合信必可用于儿童哮喘的治疗,对缓解症状和改善肺功能均能收到良好效果,尤其对小气道功能改善明显。

Clinical effectiveness of oral montelukast combined with inhaled symbicort in the treatment of children with asthma

Aim To observe the curative effect of therapeutic alliance for childish asthma with montelukast sodium and symbicort. Methods 62 cases with mild-to-moderate asthma were randomly divided into two groups, and assigned into experiment group 32 cases and control group 30 cases. The cases of experiment group were treated by montelukast sodium 5 mg orally taken once every night in addition to receiving symbicort turbuhaler （budesonide/formoterol） 80/4.5 μg twice a day in an inhaler for 12 weeks ,the cases of control group receive symbicort turbuhaler （budesonide/formoterol） 80/4.5 μg twice a day in a inhaler for 12 weeks. Clinical control, pulmonary function （PEF,FEV 1 ,FEF 25,FEF 50,FEF 75） change were observed. Results As for clinical control rate, in the 12-week experiment, the clinical control rate of experiment group is 93.7%, corresponding with control group 86.7%, there is no statistical difference in clinical control rate （P 〉 0.05 ）. As for pulmonary function, FEV1, PEF, FEF75, FEF50, FEF25 of experiment group are much better in pulmonary function,there is statistical differen compared with the untreated （P 〈 0. 01 ）. Compared with control group the improving rates of PEV1, PEF are statistically different, while the improving rates of FEF75, FEF50, FEF25 have no statistical difference （ P 〈 0. 05 ）. Conclusion The combination of Montelukast and Symbicort can be used in asthma of children,both greater in the improvement of symptom and pulmonary function, especially in the function of small airway.